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Abstract (200 words) 
Recent genetic studies have identified alleles associated with opposite effects on 
adiposity and risk of type 2 diabetes. We aimed to identify more of these variants and 
test the hypothesis that such “favourable adiposity” alleles are associated with higher 
subcutaneous fat and lower ectopic fat. We combined magnetic resonance imaging 
(MRI) data with genome-wide association studies (GWAS) of body fat % and 
metabolic traits. We report 14 alleles, including 7 newly characterized alleles, 
associated with higher adiposity, but a favourable metabolic profile. Consistent with 
previous studies, individuals carrying more “favourable adiposity” alleles had higher 
body fat % and higher BMI, but lower risk of type 2 diabetes, heart disease and 
hypertension. These individuals also had higher subcutaneous fat, but lower liver fat 
and lower visceral-to-subcutaneous adipose tissue ratio. Individual alleles associated 
with higher body fat % but lower liver fat and lower risk of type 2 diabetes included 
those in PPARG, GRB14 and IRS1, whilst the allele in ANKRD55 was paradoxically 
associated with higher visceral fat but lower risk of type 2 diabetes. Most identified 
“favourable adiposity” alleles are associated with higher subcutaneous and lower liver 
fat, a mechanism consistent with the beneficial effects of storing excess triglyceride in 
metabolically low risk depots.    
Introduction 
There are many overweight or obese individuals who do not carry the expected 
metabolic disease risks associated with higher BMI (1; 2) while some lean or normal 
weight individuals develop diseases like type 2 diabetes(3-5). We(6; 7) and others(8-
10) have previously shown that genetic variation is likely to contribute to these 
differences by increasing adiposity but lowering the risk of type 2 diabetes. We labelled 
these variants “favourable adiposity” since the alleles associated with higher BMI are 
associated with a favourable metabolic profile and lower risk of type 2 diabetes. The 
alternative alleles of the same variants could be characterized as “unfavorable lack of 
adiposity” or “limited adipose tissue storage capacity”. The identification of these 
variants differed by study. One study started with a genome-wide association study 
(GWAS) of body fat % in 76,150 individuals and showed that a common allele near 
the IRS1 gene was associated with higher adiposity but lower insulin resistance and risk 
of disease(8). The remaining studies were limited to genetic variants associated with 
fasting insulin levels at genome-wide levels of statistical confidence and used a 
combination of data and approaches to identify genetic scores of between 10 and 53 
variants that collectively were associated with opposite effects on BMI and risk of type 
2 diabetes(6; 7; 9; 10).  
More detailed characterization of these alleles revealed several insights. First, the 
alleles associated with higher BMI but lower risk of type 2 diabetes were associated 
with a lower risk of hypertension and heart disease as well as type 2 diabetes(6; 7; 9). 
Second, most of the alleles associated with higher insulin sensitivity, as identified by 
GWAS of fasting insulin levels, were associated with higher BMI or a redistribution of 
fat into the lower body, as estimated by waist-to-hip ratio(6; 7; 9; 10). Third, these 
alleles were associated with more refined measures of adipose tissue distribution: the 
alleles associated with higher BMI but lower risk of disease were also associated with 
higher adiposity in the lower body (gynoid area and legs) as measured by DEXA(9).  
The association of “favourable adiposity” alleles with higher peripheral adiposity in the 
previous studies proposed that a likely explanation for the mechanism is altered adipose 
tissue storage capacity(6; 7; 9; 10) consistent with the “adipose tissue expandability” 
hypothesis(11). To have a clear understanding about the underlying mechanisms 
associated with “favourable adiposity” in the context of the “adipose tissue 
expandability” hypothesis, we need to study whether “favourable adiposity” alleles are 
specifically associated with lower levels of ectopic fat. Furthermore, since men and 
women have different body fat distribution regulated by sex steroids(12), the study of 
underlying mechanisms separately in men and women may help elucidate the biology 
of the cardio-metabolic diseases. 
The aim of this study was to identify additional alleles associated with “favourable 
adiposity” and to combine genetic and MRI data to understand more about the 
underlying mechanisms. In contrast to most previous studies, that focused on variants 
associated with surrogate measures of insulin resistance (fasting insulin), we started 
with variants associated with altered body fat %. We describe an approach that led to 
the characterization of 14 alleles collectively associated with higher body fat % but 
lower risk of type 2 diabetes, hypertension and heart disease. We showed that these 
alleles are associated with lower ectopic fat in the liver, based on MRI data.  
 
  
Method 
UK Biobank study: UK Biobank recruited over 500,000 individuals aged 37-73 years 
(99.5% were between 40 and 69 years) between 2006-2010 from across the UK 
(supplementary table 1). The study has been described in more detail elsewhere(13).  
UK Biobank genetic data: SNP genotypes underwent extensive central quality control 
(http://biobank.ctsu.ox.ac.uk). We based our study on 451,099 individuals of white 
European descent as defined by Principal Components Analysis (PCA). Briefly, 
principal components were generated in the 1000 Genomes Cohort using high-
confidence SNPs to obtain their individual loadings. These loadings were then used to 
project all of the UK Biobank samples into the same principal component space and 
individuals were clustered using principal components 1-4. We removed 7 participants 
who withdrew from the study, and 348 individuals whose self-reported sex did not 
match their genetic sex based on relative intensities of X and Y chromosome SNP probe 
intensity. 
Measures of disease and disease related traits in UK Biobank: We used 3 cardio-
metabolic diseases: type 2 diabetes, hypertension (also represented by continuous 
measures of systolic and diastolic blood pressure) and heart disease – all using baseline 
data and following similar definitions to those used in previous GWASs 
(supplementary table 1). 
We defined type 2 diabetes cases using baseline data if 3 criteria were present: i) reports 
of diabetes at the interview, ii) at least one year gap from diagnosis without requiring 
insulin, iii) reported age at diagnosis over the age of 35 years to limit the numbers of 
individuals with slow-progressing autoimmune diabetes or monogenic forms. 
Individuals not reporting an age of diagnosis were excluded. We also excluded 
individuals diagnosed with diabetes within the year prior to the baseline study visit as 
we were unable to determine whether they were using insulin within the first year. 
Controls were individuals not fulfilling these criteria. 
We defined subjects as hypertensive if systolic blood pressure was >140 mmHg, or a 
diastolic blood pressure was >90 mmHg, or blood pressure medication was reported. 
Controls were individuals not fulfilling these criteria. For the analysis of systolic and 
diastolic blood pressure, we corrected blood pressure measures in people on 
antihypertensive drugs by adding 15 mmHg to systolic and 10 mmHg to diastolic blood 
pressure.  
We defined heart disease cases if individuals reported angina and/or a heart attack at 
the interview stage. We defined controls as individuals without these conditions.  
Identification of genetic variants associated with “favorable adiposity” 
We designed a study in three steps to identify genetic variants associated with 
“favourable adiposity” (supplementary figure 1).  
First, genetic variants associated with adiposity. We used Bio-impedance measures 
of body fat % measured by the Tanita BC418MA body composition analyser as 
measure of adiposity (N = 442,278 individuals from UK Biobank). We used a linear 
mixed model implemented in BOLT-LMM to account for population structure and 
relatedness(14). We used age, sex, genotyping platform, study centre and the first 5 
principal components as covariates in the model.  
Second, genetic variants associated with a multivariate metabolic outcome: We 
used summary statistics from published GWASs (not including UKBiobank) of 
metabolic biomarkers including body fat % (N = 120,000)(15), HDL-C (99,900)(16), 
adiponectin (29,400)(17), sex hormone binding globulin (SHBG, 21,800)(18), 
triglycerides (96,600)(16), fasting insulin (51,800)(19), and alanine transaminase 
(55,500)(20). We used these biomarkers to be consistent with our previous approach(7). 
These biomarkers are used to discriminate monogenic disorders of fat storage 
(lipodystrophy) from other monogenic conditions where insulin sensitivity and 
adiposity are affected(7; 21; 22).  
Within each GWAS, we standardized the effect sizes to correct for the differences in 
sample size and the various traits measurement unit across different GWAS: 
𝑏𝑒𝑡𝑎𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 =
𝑏𝑒𝑡𝑎
𝑠𝑒 ∗ √𝑛
 
We used metaCCA(23) to run a multivariate GWAS. The phenotype-phenotype 
correlation matrix (ΣˆYY=cov(Y, Y)) was built according to the Pearson correlation 
between any pairs of traits across genome-wide genetic variants. Genotype-genotype 
correlation matrix (ΣˆXX=cov(X, X)) was computed using reference database from 
1000 Genomes. The canonical correlation analysis in metaCCA finds the maximal 
correlation coefficient R_metaCCA between genetic variants and linear combination of 
phenotypes based on phenotype-phenotype correlation matrix. We defined genetic 
variants associated with a multivariate metabolic outcome if metaCCA p < 5x10-8. 
Third, genetic variants associated with “favourable adiposity”. We selected genetic 
variants associated with both adiposity (step 1) and a multivariate metabolic outcome 
(step 2) at p < 5x10-8 and used a hierarchical clustering approach to narrow down the 
list to ones showing a pattern of “favourable adiposity”. We calculated the frequency 
of times the variants were in the same cluster to identify “favourable adiposity” cluster 
using the “pvclust” package in R as shown before(7). 
Genetic score analysis 
We constructed the genetic score of “favorable adiposity” variants as the number of 
“favorable adiposity” alleles carried by each individual (un-weighted). We used age, 
sex, genotyping platform, study center and the first 5 ancestry principal components as 
covariates in the model.  
Additional studies for replication of the non-imaging findings  
To provide further evidence for the role of “favorable adiposity” alleles, we used 5 
cohorts that were not part of the published GWASs used in our discovery stage 
(supplementary table 1): NEO study (The Netherlands Epidemiology of Obesity; 
6,671 individuals of white European descent collected from the greater area of Leiden 
in the West of the Netherlands(24)), EXTEND (Exeter 10,000; 7,340 individuals of 
white European descent collected from South West England), GS:SFHS (Generation 
Scotland: Scottish Family Health Study; 20,000 individuals of white European descent 
collected from Scotland(25)), TÜF (Tübingen Family Study for Type 2 Diabetes; 2,679 
individuals of white European descent collected from Southern Germany(26)), and 
IMI-DIRECT (Diabetes Research on Patient Stratification; 3,029 Caucasian pre-
diabetic and Type 2 Diabetes subjects recruited by clinical centers located across 
Europe(27)).  
To further provide evidence for the role of “favorable adiposity” alleles in risk of 
cardiometabolic diseases, we used published GWAS studies of type 2 diabetes(28), 
heart disease(29) and blood pressure(30). 
Studies contributed to imaging findings (liver fat, visceral fat and subcutaneous 
fat): 
UK Biobank: We used 5,045 individuals who had available data obtained through UK 
Biobank Access Application number 9914 and 6569. Participants were MRI scanned 
as previously described(31). Briefly, a single transverse slice located at the liver was 
acquired from each subject using multi-echo spoiled-gradient-echo acquisition and 
analysed as previously described(32). Assessment of abdominal subcutaneous and 
visceral fat was described previously(33).   
NEO: Abdominal subcutaneous and visceral fat was assessed in 2,236 participants 
using MRI and were quantified by a turbo spin echo imaging protocol. At the level of 
the 5th lumbar vertebra 3 transverse images each with a slice thickness of 10 mm were 
obtained during a breath-hold. Proton (1H)-MRS of the liver was used to assess hepatic 
triglyceride content (N = 1,821)(24). 
TÜF: The TÜF study contributed subcutaneous and visceral adipose tissue 
measurements from 833 and 906 genotyped individuals, respectively, who underwent 
whole body magnetic resonance tomography. The two fat depots were quantified by an 
axial T1-weighed fast spin echo technique with a 1.5 T whole-body imager (Magnetom 
Sonata, Siemens Healthcare), as previously described(26). Liver fat measurements 
were available from 911 genotyped individuals who underwent localized 1H magnetic 
resonance spectroscopy, as described(26).  
IMI-DIRECT: The IMI-DIRECT consortium is a collaboration among investigators 
from a range of European academic institutions and pharmaceutical companies. Liver 
fat was assessed on 1,457 subjects using a multi-echo acquisition as previously 
described(34). Briefly, the liver was identified from a scout abdominal image and axial 
images were performed during suspended respiration, which were used to position a 
single slice multi-echo sequence through the liver.  
Published GWAS: We used published genome-wide association study of 
subcutaneous and visceral fat distribution as measured by CT scan or MRI(35).  
Results 
We identified 14 alleles associated with “favourable adiposity”  
Using a 3-step approach, we characterized 14 genetic variants associated with 
“favourable adiposity”. Of these variants, seven were previously known to be 
associated with a “favourable adiposity” phenotype - those in/near PPARG, LYPLAL1, 
GRB14, IRS1, PEPD, FAM13A and ANKRD55, five were known to be associated with 
a relevant trait, but not confirmed as having a “favourable adiposity” phenotype, (those 
in/near TRIB1, KLF14/MKLN1, DNAH10, VEGFA/C6orf223 and AEBP2/PDE3A) and 
two were entirely novel (those in/near MAFF and CITED2) (supplementary table 2). 
Twelve of the 14 variants had not previously been associated with body fat % at 
genome-wide levels of statistical confidence.   
In the first step (supplementary figure 1), we performed a GWAS of body fat % in 
442,278 individuals in the UK Biobank. We identified 620 variants at p<5x10-8. In the 
second step, we used published GWAS statistics from 7 circulating biomarkers of 
metabolic health and identified 33 of these 620 variants as associated with a 
multivariable metabolic phenotype. This approach identifies alleles associated with 
metabolic traits after accounting for the phenotypic correlation between higher 
adiposity and these metabolic traits (supplementary table 3 & 4, supplementary 
figure 2). For example, this approach has more power to detect alleles paradoxically 
associated with higher adiposity but a favourable metabolic profile, because the model 
accounts for the population level correlation between higher adiposity and an adverse 
metabolic profile. The resulting 33 alleles also included some alleles associated very 
strongly with higher BMI and adverse metabolic profile, such as the allele in the FTO 
gene, most likely because adjusting for body fat % in the model does not fully account 
for the adverse metabolic effects of lifelong higher adiposity. We therefore undertook 
a third step where we further refined the phenotypic characteristics of these variants by 
performing a clustering analysis. This approach led to the clustering of 14 alleles 
associated with “favourable adiposity” as defined by association with higher body fat 
%, HDL-C, SHBG and adiponectin levels, and lower triglycerides, alanine 
transaminase and fasting insulin levels (supplementary figure 3). We validated the 
effect of the 14 “favourable adiposity” alleles together in a genetic score on levels of 
metabolic biomarkers using 5 independent studies: NEO, EXTEND, GenScotland, 
TÜF and IMI-DIRECT (supplementary table 5). 
A genetic score of “favourable adiposity” alleles was associated with lower risk of 
cardiometabolic disease outcomes. 
Carrying additional "favourable adiposity" alleles was associated with higher body fat 
% and higher BMI but lower risk of type 2 diabetes, hypertension and heart disease 
(table 1). For example, the 10% of people carrying the most “favourable adiposity” 
alleles had approximately 1.04% higher body fat % (95%CI [0.95,1.13], p=6x10-115) 
and 0.4 kg/m2 higher BMI ([0.32,0.45], 3x10-29) but 0.66 OR lower risk of type 2 
diabetes ([0.61,0.72], 7x10-23), 0.87 lower risk of hypertension ([0.84,0.90], 1x10-19) 
and 0.84 OR lower risk of heart disease ([0.80,0.89], 6x10-10) compared to the 10% of 
people carrying the fewest “favourable adiposity” alleles (data from UK Biobank) 
(figure 1). These effects were similar in men and women and when we removed the 
seven known "favourable adiposity" variants from the analysis (table 1). These 
associations were similar when using data from published GWASs (supplementary 
table 6). For each of the 14 individual variants, the body fat % increasing allele was 
associated with at least one of lower risk of type 2 diabetes, lower risk of heart disease 
or lower diastolic or systolic blood pressure in UK Biobank except the variant at the 
AEBP2 locus (supplementary figure 4). In published GWAS data the exceptions were 
the variants at the AEBP2 and MAFF loci (supplementary table 6).  
Individual “favourable adiposity” alleles were associated with heterogeneous effects 
on waist-to-hip ratio. 
Five of the individual 14 variants were previously identified as associated with waist-
to-hip ratio(36). Previous studies have pointed out that the disease-protective effect of 
these alleles is likely to be due to their association with redistribution of the extra fat 
into the lower body (defined by lower waist-to-hip ratio). We therefore examined the 
alleles’ association with waist-to-hip ratio in more detail. Carrying more “favourable 
adiposity” alleles was associated with lower waist circumference (p=3.7x10-5) but 
higher hip circumference (2.3x10-109) in women. However, in men, carrying more 
“favourable adiposity” alleles was associated with higher waist circumference (1.7x10-
40), higher hip circumference (1.8x10-53) and no effect on waist-to-hip ratio 
(supplementary table 7). These associations were robust when limiting the variants to 
the 7 not previously identified as having a “favourable adiposity” phenotype 
(supplementary table 7). The individual variants were associated with heterogeneous 
effects on waist-to-hip ratio. Most notably, for two variants, those in/near PPARG and 
ANKRD55, the “favourable adiposity” allele was not associated with lower waist-to-
hip ratio in women, and for ANKRD55, it was associated with higher waist-to-hip ratio 
(figure 2). 
“Favourable adiposity” alleles were associated with less liver fat and more abdominal 
subcutaneous fat. 
We next investigated the associations between the “favourable adiposity” variants and 
MRI measures of subcutaneous, visceral and liver fat using data from 9,434  individuals 
and 4 studies – the first wave of UK Biobank imaging data (n=5,045), NEO (2,236), 
IMI-DIRECT (1,323) and TÜF (906). A fifth set of data did not include liver fat and 
came from a published meta-analysis of 13 studies with abdominal MRI or CT scans 
of 18,332 individuals(35).  
The genetic score of “favourable adiposity” alleles was associated with lower visceral-
to-subcutaneous adipose tissue ratio p=2x10-14) in both men and women. This effect 
was driven by association with more subcutaneous fat (p=2x10-14; table 2, figure 3). 
All 14 individual genetic variants were associated with higher subcutaneous adipose 
tissue, seven at p<0.05 (in/near DNAH10, FAM13A, GRB14, KLF14, LYPLAL1, IRS1 
and PPARG). Nine individual “favourable adiposity” alleles were associated with lower 
visceral-to-subcutaneous adipose tissue volume ratio, all at p < 0.05 (in/near CITED2, 
DNAH10, FAM13A, KLF14, LYPLAL1, IRS1, PPARG, TRIB1 and VEGFA; 
supplementary figure 4, supplementary table 8). Paradoxically, the “favourable 
adiposity” alleles in/near ANKRD55 and PEPD were associated with higher visceral-
to-subcutaneous adipose tissue volume ratio (p=0.001 and 0.02, respectively). 
The genetic score of “favourable adiposity” was associated with lower liver fat in 
women (p=6.3x10-9) but was not associated with liver fat in men (p=0.8; table 2, figure 
3). These effects were robust when limiting the variants to the 7 not previously 
identified as having a “favourable adiposity” phenotype (table 2). For 11 individual 
variants, the allele associated with higher subcutaneous fat was associated with lower 
liver fat, four with p<0.05 (in/near CITED2, GRB14, PPARG and TRIB1 
(supplementary figure 4, supplementary table 8).  
Sensitivity analysis of liver fat.  
We performed three sensitivity analyses to assess whether the effect of “favourable 
adiposity” alleles on lower liver fat was affected by menopause, inclusion of type 2 
diabetes patients or alcohol consumption.  
First, menopause leads to a redistribution of adipose tissue towards more central obesity 
and an android phenotype(37; 38). To study whether or not the association with liver 
fat in women was influenced by menopausal status, we divided women from the UK 
Biobank and TÜF studies into pre- and post-menopausal status. The association 
between “favourable adiposity” alleles and lower liver fat in pre-menopausal women 
was twice that (-0.258 % [-0.223,-0.293]; p=0.002; n=433) of post-menopausal women 
(-0.124 % [-0.106,-0.142]; p=0.002; n=2,356) but the difference was not statistically 
meaningful (Pdifference=0.14; supplementary table 9). 
Second, fatty liver disease is very common (>50%) in patients with type 2 diabetes(39). 
To check whether inclusion of people with type 2 diabetes had affected the association 
with liver fat, we ran the tests in UK Biobank individuals excluding people diagnosed 
with type 2 diabetes (n=222) from the analysis of liver fat. The association of 
“favourable adiposity” alleles with liver fat remained similar after exclusion of patients 
with type 2 diabetes in all, men and women (all Pdifference>0.7; supplementary table 
10). 
Third, the most common cause of increased fat in the liver is alcohol consumption 
which is more prevalent in men(40; 41). To study whether or not the lack of association 
with liver fat in men was due to greater alcohol consumption, we assessed the effect of 
“favourable adiposity” alleles on liver fat in men defined as heavy, moderate and non-
drinkers based on self-report alcohol questionnaires. The “favourable adiposity” alleles 
were not associated with liver fat in any of the three groups (supplementary table 11).  
Discussion 
We characterized 14 genetic variants associated with “favourable adiposity”. Our study 
adds to previous studies(6; 7; 9; 10) in several ways. First, we outlined a new approach 
which leads to the identification of more “favourable adiposity” variants. Second, we 
provide more clarity about which individual alleles are likely “favourable adiposity” 
alleles and how they affect metabolic traits and diseases. Third, we used MRI data 
which strongly suggests these variants have a collective effect on lower liver fat as well 
as higher subcutaneous fat but they have little detectable effect on visceral fat. Finally, 
we provide a template for detecting alleles with apparently paradoxical effects on 
adiposity and disease using a wide variety of publically accessible GWAS data. In 
addition, our results strengthen previous observations including the “favourable 
adiposity” effect is not driven by altered body shape in men detectable by waist-to-hip 
ratio (6). 
Of the 14 variants detected, 12 had been associated with at least one metabolic trait, 
including fasting insulin (those in/near LYPLAL1, GRB14, IRS1, FAM13A, ANKRD55 
and PEPD (42)), lipid levels (those in/near GRB14, IRS1, KLF14, TRIB1 and DNAH10 
(16)), adiponectin (those in/near TRIB1, DNAH10 and AEBP2(17)) and alanine 
transaminase (TRIB1(20)). However, only two were known to be associated with body 
fat % (those in/near GRB14 and IRS1(15)) at genome-wide levels of statistical 
confidence. Our data provides several insights about individual variants. First, the 
alleles at PPARG, GRB14 and IRS1 are associated with higher body fat % but lower 
liver fat and lower risk of type 2 diabetes. Second, the allele in ANKRD55 is 
paradoxically associated with higher visceral fat but lower risk of type 2 diabetes. In 
agreement with this finding, this variant is in high linkage disequilibrium (R2= 0.97) 
with another variant (rs459193) found to associate with lower waist circumference, but 
higher 2-houre glucose levels(43). Third, the allele in TRIB1 is associated with higher 
body fat %, lower visceral fat, lower liver fat and lower risk of heart disease and 
hypertension but it does not have any detectable effect on type 2 diabetes. Fourth, 4 
variants we previously noted as favourable adiposity were not detected in this study. 
These variants (in or near PDGFC, PEPD, RSPO3 and TET2) may alter body fat 
distribution or other aspects of body composition without altering overall body fat %, 
and hence were not detected at p<5x10-8 in stage 1. 
A key question is whether or not the “favourable adiposity” effect is entirely due to 
preferential storage of the excess adiposity in the lower body as proposed before(36; 
44). We made two general observations. First, despite similar effects on higher body 
fat % and lower risk of disease in each sex, the protective effect in men was not 
characterized by preferentially more fat in the lower body, as estimated by waist-to-hip 
ratio, consistent with our previous observation(6). Second, the individual variants were 
associated with heterogeneous effects on waist-to-hip ratio even within women. For 
example the allele in/near ANKRD55 was associated with “favourable adiposity” but 
higher waist-to-hip ratio in women. 
Having established that the “favourable adiposity” effect is not driven by preferential 
storage of fat in the lower body, as estimated by waist-to-hip ratio, in men, we examined 
more detailed measures of fat redistribution using MRI data. The association with lower 
liver fat was only detected in women. Our sensitivity analyses did not find hormonal 
differences due to menopause, alcohol consumption or type 2 diabetes as possible 
explanations for sex differences. We would expect the “favourable adiposity” alleles to 
be associated with liver fat in non-drinkers or moderate drinkers if the alcohol intake in 
men confounded the association. However, the analysis stratified by alcohol intake in 
men did not show any association. The lack of association with visceral fat suggests 
that these alleles were not protecting from disease due to lower visceral fat. This 
observation is consistent with some studies which showed lower ectopic fat 
accumulation in the liver may be more important than visceral fat in protection from 
risk of type 2 diabetes(45). A caveat to this conclusion is that we used a marker of liver 
fat, alanine transaminase, as one of the metabolic biomarkers to identify the variants, 
and therefore will be biased towards those that affect liver more than visceral fat. 
Our approach provides a framework for identifying additional alleles with apparently 
paradoxical effects on adiposity and disease. A previous study(9) used a simple and 
effective approach by taking published GWAS data and selecting all variants associated 
with higher fasting insulin adjusted for BMI, lower HDL-C and higher triglycerides  at 
p<0.005 for each of the three traits. However, this approach has limitations for two 
reasons, first it applies an arbitrary cut-off for the three traits, and second, it does not 
use information from other biomarkers. We combined GWASs of seven metabolic 
biomarkers and used a multivariate test that does not require individual trait 
associations to reach a certain statistical threshold. We showed that our method 
performs well, as it was able to identify the 7 variants previously known to be associated 
with “favourable adiposity” as well as 7 additional variants that we then validated in 
independent GWAS data. Furthermore, by including SHBG, adiponectin and ALT in 
the model, we had more power to detect “favourable adiposity” variants 
(supplementary table 12). 
The identification of “favourable adiposity” alleles highlights genes that may be targets 
for novel insulin-sensitizing agents. The allele in PPARG provides an important proof 
of principle because thiazolidinediones are PPAR-γ agonists and appear to lower 
glucose levels despite increasing the patient’s weight by activating adipocyte 
differentiation, which redistributes fat away from liver towards an expanded 
subcutaneous depot(46; 47). The variants identified in our study do not identify which 
genes they are acting through; however, previous studies suggest some strong 
candidates. For example, TRIB1 encodes a protein critical for adipose tissue 
maintenance and suppression of metabolic disorders(48). Mice lacking Trib1 show 
diminished adipose tissue mass and increased lipolysis even when on a normal diet(48). 
GWAS studies in humans have implicated TRIB1 in lipid metabolism(16) and 
regulation of hepatic lipogenesis(20). Higher levels of VEGF-A in mice can facilitate 
healthy expansion of adipose tissue and protect from lipotoxicity and metabolic 
disease(49). CITED2 is required for optimal PPARγ activation(50). FAM13A encodes 
a protein enriched in mature adipocytes and plays an important role in the insulin 
signaling cascade(51) by protecting IRS1 (insulin receptor substrate 1) from 
degradation(51). The proteins encoded by IRS1 and CCDC92 are associated with 
adipogenesis, lipid accumulation and adipocyte differentiation ability(9; 51). 
Functional studies suggest DNAH10 is involved in adipocyte differentiation 
capacity(9). KLF14 is a master regulator of gene expression in adipose tissue(52) 
associated with adipocyte cell size in humans(53). MAP3K1 regulates expression of 
IRS1(54). LYPLAL1, as a triglyceride lipase, is over-expressed in subcutaneous 
adipocytes of obese people to maintain triglycerides metabolism(55). The regulation of 
Grb14 expression in adipose tissue may play a physiological role in insulin 
sensitivity(56). AEBP2 regulates a gene encoding a fatty acid-binding protein. 
Our study had a number of limitations. First, we used 7 metabolic biomarkers from 
published GWASs in our multivariate analysis. The sample size for each GWAS was 
different: ranging from 21,800 individuals from GWAS of SHBG to 99,900 from the 
GWAS of lipids. These differences, caused by using GWAS meta-analysis data from 
different studies, will have limited our power, and led to less accurate estimates of the 
correlation between phenotypes compared to having the same sample size for all 
phenotypes. Second, the published GWASs of biomarkers were performed in men and 
women together rather than in a sex specific way. As men and women have different 
body fat distribution, it seems necessary to perform the discovery of “favourable 
adiposity” variants in men and women separately when data becomes available. Third, 
we used bio-impedance measures of body fat % as measure of adiposity in the discovery 
step. This measure of adiposity is an imprecise measure and is not as accurate in 
calculating body fat % in obese individuals or people with higher muscle mass(57). 
However, it’s availability in 442,278 individuals meant it represented a powerful 
dataset from which to start(58). Fourth, individual variants had subtle effect sizes; all 
variants were associated with at least one disease, with the body fat % increasing allele 
associated with lower risk except the one at AEBP2 locus; although this variant had a 
paradoxical effect on adiposity and metabolic biomarkers with significant association 
between body fat % increasing allele and higher adiponectin (p= 4.76x10-8), higher 
HDL-C (p=2.83x10-6) and lower triglycerides (p=0.003; supplementary table 4). 
To yield a better understanding of how “favourable adiposity” protects against 
cardiometabolic disease, more studies in future are warranted. First, it will be important 
to test the association of “favourable adiposity” variants with pancreatic fat as a 
potential cause of β-cell dysfunction that will inform the associations with type 2 
diabetes. Second, there are substantial ethnic differences in diabetes risk by BMI with 
South Asians having a much higher risk of type 2 diabetes for a given BMI compared 
to Europeans(59). Study of the genetics of “favourable adiposity” in different ethnic 
groups may provide important insights into the mechanisms underpinning the 
significant ethnic differences in diabetes risk. 
In summary, our study provides further genetic evidence that the balance of 
subcutaneous to ectopic liver fat is an important factor for type 2 diabetes, heart disease 
and hypertension. This finding is consistent with data from monogenic forms of 
lipodystrophy and the importance of an expandable subcutaneous adipose tissue as a 
protective disease mechanism and limited adipose storage capacity as a risk mechanism 
(based on the opposite alleles) as proposed in previous studies(60-62). 
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Tables 
 
 
 
 
 
 
 
 
 
 
Table 1. The effect of “favourable adiposity” genetic score on measures of adiposity and cardiometabolic disease outcome in the UK Biobank 
study. Effects are per carrying additional adiposity allele. 95% CI: 95% confidence interval; P: p-value; N: number; OR: odds ratio. 
  14 SNPs 7 “additional” SNPs  
Trait/disease Analysis Effect 95% CI P Effect 95% CI P N  (cases vs. controls) 
Body fat % ALL 0.17 0.169, 0.171 6x10-263 0.15 0.149, 0.151 1x10-105 443,000 
Women 0.15 0.148, 0.152 3.5x10-116 0.14 0.138, 0.142 8.9x10-52 240,882 
Men 0.19 0.188, 0.192 1x10-165 0.16 0.158, 0.162 3x10-61 202,118 
BMI (kg/m2) ALL 0.040  0.039, 0.041 3.6x10-45 0.045 0.044, 0.047 4.5x10-30 449,359 
Women 0.041 0.039, 0.042 3x10-28 0.047 0.045, 0.049 1.9x10-19 243,797 
Men 0.039 0.038, 0.041 1.6x10-22 0.042 0.040, 0.045 6x10-14 205,528 
Type 2 
diabetes (OR) 
ALL 0.954  0.948, 0.960 4x10-44 0.966 0.957, 0.975 1.9x10-13 14,371 vs. 428,017 
Women 0.950 0.939, 0.961 3x10-18 0.962 0.946, 0.977 2x10-6 4,713 vs. 236,073 
Men 0.960 0.948, 0.964 5x10-26 0.966 0.955, 0.978 1x10-8 9,076 vs. 192,344 
Heart disease  
(OR) 
ALL 0.984 0.980, 0.989 3x10-14 0.982 0.976, 0.988 1.5x10-9 37,741 vs. 318,892 
Women 0.987 0.980, 0.994 0.0003 0.981 0.971, 0.991 0.0003 12,270 vs. 184,550 
Men 0.982 0.977, 0.987 2x10-11 0.983 0.975, 0.990 2.6x10-6 25,363 vs. 134,433 
Hypertension  
(OR) 
ALL 0.987 0.985, 0.989 1x10-33 0.989 0.986, 0.992 3x10-13 241,691 vs. 206,525 
Women 0.988 0.985, 0.991 2x10-16 0.989 0.985, 0.993 3x10-7 114,713 vs. 128,623 
Men 0.985 0.981, 0.988 1.7x10-19 0.987 0.983, 0.992 1.6x10-7 126,978 vs. 77,902 
Systolic blood 
pressure 
(mmHg) 
ALL -0.173  -0.174, -0.172 9x10-46 -0.139 -0.141, -0.138 3.6x10-16 450,075 
Women -0.163 -0.165, -0.162 1x10-22 -0.134 -0.136, -0.132 1x10-8 244,183 
Men -0.206 -0.208, -0.205 7.9x10-27 -0.161 -0.163, -0.159 2x10-9 205,892 
Diastolic 
blood pressure 
(mmHg) 
ALL -0.074 -0.075, -0.073 7x10-24 -0.085 -0.087, -0.083 1x10-16 449,322 
Women -0.078 -0.080, -0.077 1.6x10-14 -0.093 -0.095, -0.091 1x10-10 243,732 
Men -0.073 -0.074, -0.071 1.9x10-10 -0.081 -0.083, -0.079 3.5x10-7 205,590 
 Table 2. The effect of “favourable adiposity” genetic score on (MRI/CT scan) measures of abdominal adipose tissue using data from 5 studies. 
Effects are per carrying additional adiposity allele. 95% CI: 95% confidence interval; P het: P of heterogeneity test across the 5 studies. 
  14 SNPs 7 “additional” SNPs 
 Analysis Beta 95% CI P P het Beta 95% CI P P het 
Subcutaneous 
adipose tissue 
(Litres) 
All 0.054 0.042, 0.067 2x10-14 0.36 0.048 0.029, 0.067 9.6x10-7 0.38 
Women 0.032 0.016, 0.048 6x10-5 0.55 0.032 0.010, 0.054 3x10-3 0.89 
Men 0.051 0.035, 0.067 2.5x10-11 0.16 0.045 0.022, 0.064 4.9x10-5 0.35 
Visceral 
adipose tissue 
(Litres) 
All 0.005 -0.007, 0.014 0.4 0.69 -0.002 -0.016, 0.011 0.84 0.94 
Women -0.007 -0.018, 0.005 0.2 0.28 -0.009 -0.025, 0.005 0.21 0.6 
Men 0.011 0.000, 0.020 0.05 0.05 0.007 -0.009, 0.020 0.43 0.34 
VATSAT 
ratio 
All -0.005 -0.007, -0.004 2x10-14 0.15 -0.005 -0.008, -0.004 4x10-9 0.75 
Women -0.005 -0.007, -0.003 1x10-10 0.46 -0.006 -0.008, -0.004 9x10-8 0.93 
Men -0.004 -0.005, -0.002 7x10-7 0.03 -0.004 -0.006, -0.002 4x10-4 0.16 
Liver fat (%) 
All -0.087 -0.124, -0.051 5.6x10-6 0.015 -0.060 -0.115, -0.009 0.02 0.015 
Women -0.170 -0.225, -0.110 6.3x10-9 0.26 -0.133 -0.216, -0.055 1x10-3 0.57 
Men -0.005 -0.055, 0.041 0.8 0.16 0.000 -0.069, 0.069 0.99 0.086 
 
Figures 
Figure 1. Carrying more “favourable adiposity” alleles was associated with higher 
adiposity but lower risk of type 2 diabetes (a), heart disease (b) and hypertension (c). 
We divided individuals from UK Biobank into 10 centiles based on their “favourable 
adiposity” genetic score (x vector). The distribution of “favourable adiposity” genetic 
score is shown in black and the case/control proportion is shown in red per each centile. 
Figure 2. The individual variants were associated with heterogeneous effects on waist-
to-hip ratio. Most notably, for two variants, those in/near PPARG and ANKRD55, the 
“favourable adiposity” allele was not associated with lower waist-to-hip ratio in 
women, and for ANKRD55, it was associated with higher waist-to-hip ratio. For eleven 
variants (those in/near IRS1, TRIB1, CITED2, FAM13A, VEGFA, AEBP2, KLF14, 
LYPLAL1, DNAH10, MAFF and GRB14) the “favourable adiposity” allele was 
associated with lower waist-to-hip ratio in women, whilst for the variant in/near PEPD 
there was no clear association with waist-to-hip ratio in either sex. The x vector 
illustrates the effect on body fat % in men (right plot) and women (left plot). The y 
vector illustrates the effect on waist-to-hip ratio. Data is from UK Biobank population. 
Figure 3. The effect of “favourable adiposity” genetic score on (MRI/CT scan) 
measures of abdominal adipose tissue using data from 5 studies. The x-axis is the effect 
size per carrying additional “favourable adiposity” allele.  
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